SCHEMBL2771632

SCHEMBL2771632

O=C(Nc1cccc2c1CCc1cccc3[nH]nc-2c13)C1CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 2/20 0.44
MAPK9 P45984 2/20 0.44
MAPK10 P53779 2/20 0.44
PARP14 Q460N5 1/20 0.44
KIT P10721 2/20 0.44
KDR P35968 2/20 0.44
FLT3 P36888 2/20 0.44
LMNA P02545 2/20 0.42
CASP3 P42574 1/20 0.41
GSK3B P49841 4/20 0.40
CLK2 P49760 2/20 0.40
DYRK1A Q13627 2/20 0.40
PIM1 P11309 2/20 0.40
CSNK2A1 P68400 2/20 0.40
CLK3 P49761 1/20 0.40
PIK3CD O00329 1/20 0.40
PIK3CB P42338 1/20 0.40
PDPK1 O15530 2/20 0.38
ALDH1A1 P00352 4/20 0.38
TSHR P16473 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2768161 0.77 KDR (0.50) MAPK8MAPK9MAPK10KITKDR
SCHEMBL2768004 0.77 MAPK8 (0.52) MAPK8MAPK9MAPK10KITKDR
SCHEMBL2771305 0.73 MAPK8 (0.57) MAPK8MAPK9MAPK10KITKDR
SCHEMBL2768700 0.72 MAPK10 (0.52) MAPK8MAPK9MAPK10KITKDR
SCHEMBL2768727 0.72 MAPK8 (0.52) MAPK8MAPK9MAPK10KITKDR
SCHEMBL2769394 0.71 MAPK10 (0.76) MAPK8MAPK9MAPK10KITKDR
SCHEMBL2769418 0.70 ABL1 (0.46) MAPK8MAPK9MAPK10KITKDR
SCHEMBL2769382 0.68 NPC1 (0.44) MAPK8MAPK9MAPK10KITKDR
SCHEMBL2768451 0.68 NPSR1 (0.47) MAPK8LMNAALDH1A1TSHRNPSR1
SCHEMBL2768810 0.67 KMT2A (0.50) MAPK10LMNAALDH1A1TSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1479670-B1 NOVEL FUSED RING INDAZOLE COMPOUNDS EISAI R&D MAN CO LTD (JP) 2010-04-21 EP disclosed
EP-1479670-B1 NOVEL FUSED RING INDAZOLE COMPOUNDS EISAI R&D MAN CO LTD (JP) 2010-04-21 EP disclosed
US-7390797-B2 Fused indazole compounds EISAI CO., LTD. (JP) 2008-06-24 US disclosed
US-7390797-B2 Fused indazole compounds EISAI CO., LTD. (JP) 2008-06-24 US disclosed
US-7390797-B2 Fused indazole compounds EISAI CO., LTD. (JP) 2008-06-24 US disclosed
US-20060111419-A1 Novel fused indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2006-05-25 US disclosed
EP-1479670-A1 NOVEL FUSED RING INDAZOLE COMPOUNDS Eisai Co., Ltd. (JP) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111419-A1 Novel fused indazole compounds MAP2K3, MAP3K11, MAP2K2 MAPK8 38/4885MAPK9 42/4885MAPK10 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.